Literature DB >> 8158767

Squamous cell carcinoma of the penis. IV. Prognostic factors of survival: analysis of tumor, nodes and metastasis classification system.

S Horenblas1, H van Tinteren.   

Abstract

Various prognostic factors of survival were assessed in 118 patients with squamous cell carcinoma of the penis treated at The Netherlands Cancer Institute between 1956 and 1989. Using the clinical parameters of the tumor, nodes and metastasis classification system of the International Union Against Cancer (1978 version) and a differentiation system consisting of 3 grades the prognostic relevance for survival was analyzed. T category, N category and grade of differentiation showed statistical significance in the univariate analysis. Patients with small tumors, clinically negative nodes and well differentiated tumors showed a favorable prognosis. Only N category and grade were independent prognostic factors of survival using the Cox proportional hazards model. On the basis of the survival analysis a stage grouping consisting of 3 stages is proposed with 5-year survival probabilities for stages 1, 2 and 3 of 93%, 55% and 30%, respectively. A revised version of the tumor, nodes and metastasis system was introduced in 1987. This latest version was analyzed with the previous method, which was used in this report, and prognostically important and clinically useful parameters, such as the size of the primary tumor and evidence of fixation of the regional lymph nodes, have been discarded. The changes in the revised version seem to have little relevance to clinical staging. The revised version should be considered a histopathological classification only.

Entities:  

Mesh:

Year:  1994        PMID: 8158767     DOI: 10.1016/s0022-5347(17)35221-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

1.  A case of local advanced penile cancer treated with multimodality therapy.

Authors:  Manabu Kato; Norihito Soga; Kiminobu Arima; Yoshiki Sugimura
Journal:  Int J Clin Oncol       Date:  2010-04-16       Impact factor: 3.402

Review 2.  [The significance of inguinal lymphadenectomy in carcinoma of the penis].

Authors:  E Preis; G Jakse
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

3.  Penile cancer: a case for guidelines.

Authors:  N P Munro; P J Thomas; G P Deutsch; N J Hodson
Journal:  Ann R Coll Surg Engl       Date:  2001-05       Impact factor: 1.891

Review 4.  Advanced penile cancer.

Authors:  Jonathan E Heinlen; David D Buethe; Daniel Joseph Culkin
Journal:  Int Urol Nephrol       Date:  2011-08-04       Impact factor: 2.370

Review 5.  [Organ-sparing surgery for penile cancer].

Authors:  B Schlenker; C Gratzke; D Tilki; E Hungerhuber; P Schneede; O Reich; C G Stief; M Seitz
Journal:  Urologe A       Date:  2008-07       Impact factor: 0.639

Review 6.  Penile preserving and reconstructive surgery in the management of penile cancer.

Authors:  Arthur L Burnett
Journal:  Nat Rev Urol       Date:  2016-03-22       Impact factor: 14.432

Review 7.  How accurate are present risk group assignment tools in penile cancer?

Authors:  Vincenzo Ficarra; G Novara; R Boscolo-Berto; W Artibani; M W Kattan
Journal:  World J Urol       Date:  2008-06-17       Impact factor: 4.226

8.  Contemporary management of penile cancer including surgery and adjuvant radiotherapy: an experience in Taiwan.

Authors:  Miao-Fen Chen; Wen-Cheng Chen; Chun-Te Wu; Cheng-Keng Chuang; Kwai-Fong Ng; Joseph Tung-Chieh Chang
Journal:  World J Urol       Date:  2003-12-05       Impact factor: 4.226

9.  [Characterization of the EGF receptor status in penile cancer : retrospective analysis of the course of the disease in 45 patients].

Authors:  C Börgermann; K J Schmitz; S Sommer; H Rübben; S Krege
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

Review 10.  The role of pathologic prognostic factors in squamous cell carcinoma of the penis.

Authors:  Antonio L Cubilla
Journal:  World J Urol       Date:  2008-09-03       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.